XML 67 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2017
Dec. 29, 2017
Jun. 30, 2020
Apr. 30, 2020
Mar. 31, 2020
Jan. 31, 2020
Aug. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Oct. 31, 2018
Apr. 30, 2018
Mar. 31, 2018
Sep. 30, 2015
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2018
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues                           $ 272,824   $ 267,187   $ 643,945 $ 1,594,461  
Grant funding liability                           6,859,155       6,859,155   $ 7,474,310
Advaccine | Customer Concentration Risk                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Accounts receivable                           0       0   7,100,000
Revenue under collaborative research and development arrangements                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues                           82,923   74,102   122,538 145,602  
Advaccine | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Upfront payment received                                   3,000,000.0    
Additional revenue to be achieved                                   206,000,000.0    
Collaboration Agreement, Payment Earned                                   $ 2,000,000.0    
Royalty period                                   10 years    
Revenues                             $ 5,000,000.0          
Annual maintenance fee                                   $ 1,500,000    
Annual maintenance period                                   5 years    
Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues                             $ 5,000,000.0     $ 0    
ApolloBio | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Upfront payment received                       $ 23,000,000.0         $ 23,000,000.0 23,000,000.0    
Additional revenue to be achieved                                   $ 20,000,000.0    
Royalty period                                   10 years    
Period from effective date for termination                                   1 year    
Territory expansion option period   3 years                                    
Proceeds received in upfront payment                       19,400,000                
Advisory fees                       960,000                
Number of days written notice before termination                                   90 days    
ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Foreign corporate income taxes reducing upfront payment                       2,200,000                
Foreign non-corporate income taxes reducing upfront payment                       $ 1,400,000                
AstraZeneca                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Revenues               $ 2,000,000.0 $ 2,000,000.0                      
AstraZeneca | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Upfront payment received $ 27,500,000                       $ 27,500,000              
Anticipated development and regulatory event based payment receivable milestones                                   $ 125,000,000    
Anticipated commercial event based payment receivable milestones                                   115,000,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received       $ 6,900,000                                
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received                     $ 56,000,000                  
Collaborative agreement, period to receive funding for research and development                     5 years                  
Funding received for research and development                           2,100,000   1,800,000   4,400,000 2,900,000  
Grant funding liability                           316,000       316,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received           $ 9,000,000.0                            
Funding received for research and development                           1,100,000   5,800,000   3,500,000 8,100,000  
Grant funding liability                           2,900,000       2,900,000    
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received       5,000,000.0                                
Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Collaborative agreement, funding to be received       $ 1,300,000                                
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Funding received for research and development         $ 5,000,000.0                 0   850,000   893,000 913,000  
Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Funding received for research and development             $ 1,100,000     $ 2,200,000           36,000     170,000  
Grant funding liability                           575,000       575,000    
Department of Defence | Collaborative Arrangement, Product                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Contra-research and development expense                           13,400,000   $ 0   21,200,000 $ 0  
Accounts receivable                           12,900,000       12,900,000   $ 11,400,000
Deferred grant funding, from affiliate                           $ 3,000,000.0       $ 3,000,000.0    
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Funding received for research and development     $ 54,500,000                                  
Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device                                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                                        
Purchase price, procurement contract     $ 16,600,000